Oct. 9, 2013, 4:57 PM
- Acura Pharmaceuticals (ACUR) +11.8% AH after announcing a settlement of patent litigation with Par Pharmaceutical (PRX) and Impax Labs (IPXL) over the pain drug Oxecta.
- According to the terms, PRX may launch its generic Oxecta product in the U.S., through the grant of a non-exclusive license which requires it to pay ACUR royalties in the range of 10%-15% of PRX's net profits from the sale.
- IPXL may launch its generic Oxecta product in the U.S. through the grant of a non-exclusive, royalty-free license.
Sep. 12, 2012, 4:04 PM
Stifel Nicolaus ups its target from $8 to $11 on Santarus (SNTS +5%) on the back of its highly successful Phase 3 results for Rifamycin SV MMX in traveler’s diarrhea, and it's successful appeal against Par Pharmaceuticals (PRX). The firm thinks that Zegerid will gain an extra $35M-$45M in annual sales as a result of the court decision, and it maintains a Buy rating on the stock.| Sep. 12, 2012, 4:04 PM
Jul. 16, 2012, 9:10 AM
Jul. 16, 2012, 8:24 AM
TPG agrees to acquire Par Pharmaceutical (PRX) for $1.9B, or $50/share, which represents a 37% premium over Par's closing price on Friday. Shares +36% premarket. (PR)| Jul. 16, 2012, 8:24 AM
May 30, 2012, 12:26 PM
Shares of Amarin (AMRN -3.5%) give back much of yesterday's pop on news that Teva Pharmaceutical (TEVA) and Par Pharmaceutical (PRX) lost their bid to sell the generic form of Lovaza. The stock had rocketed higher on perceptions that the court ruling would clear the way for Amarin's AMR101 to launch and price without competition from generic Lovaza products.| May 30, 2012, 12:26 PM | 2 Comments
Jan. 13, 2012, 1:15 PM
A union benefits fund has filed a class-action suit against Walgreen (WAG) and generic drugmaker Par Pharmaceutical (PRX), accusing them of carrying out "at least two widespread schemes to overcharge" for drugs. The lawsuit claims a variety of parties were charged 2x-4x as much as they should have been for the filling of prescriptions involving Par's drugs. (yesterday)| Jan. 13, 2012, 1:15 PM
Oct. 18, 2011, 2:41 PM
Oct. 17, 2011, 11:06 AM
Par Pharmaceutical (PRX -2.7%) trades lower after saying late Friday that it's challenging a federal rule that it claims infringes on its first-amendment right to promote its anorexia treatment Megace ES. Doctors feel the drug could benefit a variety of patients outside the FDA approved AIDS-only spectrum, but the company says the FDA is blocking it from discussing treatment options.| Oct. 17, 2011, 11:06 AM
Aug. 24, 2011, 12:27 PM
Par Pharmaceutical (PRX +5%) agrees to acquire privately held Anchen Pharmaceuticals for $410M in cash, a move that will boost the generic drug maker's current pipeline and add to its R&D capabilities.| Aug. 24, 2011, 12:27 PM